Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen N Davis

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Expert Opinion on Drug Safety|August 8, 2025
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patientsDamla N Costa, Rana Malek, Stephen N Davis
Clinical Cornerstone|August 31, 2006
Overcoming psychological barriers to insulin use in type 2 diabetesStephen A Brunton, Stephen N Davis, Susan M Renda
Clinical Cornerstone|August 31, 2006
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentationStephen A Brunton, Stephen N Davis, Susan M Renda
Metabolism: Clinical and Experimental|March 14, 2015
Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individualsNino G Joy, Donna B Tate, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2013
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Therapeutics and Clinical Risk Management|March 30, 2016
Concentrated insulins: the new basal insulinsElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Investigational Drugs|April 22, 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetesElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Drug Safety|June 6, 2014
The cardiovascular effects of insulinLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|December 18, 2012
A review of the efficacy and safety of oral antidiabetic drugsStephanie Aleskow Stein, Elizabeth Mary Lamos, Stephen N Davis
Expert Opinion on Pharmacotherapy|November 3, 2012
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitusElizabeth Mary Lamos, Stephanie Aleskow Stein, Stephen N Davis
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Safety|August 8, 2025
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patientsDamla N Costa, Rana Malek, Stephen N Davis
Clinical Cornerstone|August 31, 2006
Overcoming psychological barriers to insulin use in type 2 diabetesStephen A Brunton, Stephen N Davis, Susan M Renda
Clinical Cornerstone|August 31, 2006
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentationStephen A Brunton, Stephen N Davis, Susan M Renda
Metabolism: Clinical and Experimental|March 14, 2015
Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individualsNino G Joy, Donna B Tate, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2013
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Therapeutics and Clinical Risk Management|March 30, 2016
Concentrated insulins: the new basal insulinsElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Investigational Drugs|April 22, 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetesElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Drug Safety|June 6, 2014
The cardiovascular effects of insulinLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|December 18, 2012
A review of the efficacy and safety of oral antidiabetic drugsStephanie Aleskow Stein, Elizabeth Mary Lamos, Stephen N Davis
Expert Opinion on Pharmacotherapy|November 3, 2012
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitusElizabeth Mary Lamos, Stephanie Aleskow Stein, Stephen N Davis
Pageof 13